Every Cat Logo

Transdermal gabapentin penetration in cats

W19-039    Assessment of transdermal penetration of gabapentin in cats.
(A Winn-funded grant project final progress report)

Principal Investigators: Jennifer Slovak; Nicolas Villarino; New York City Animal Medical Center

The investigators have completed their study enrolling a total of 23 cats in the pilot transdermal gabapentin study. Initially, eight of the client-owned cats were administered transdermal gabapentin in a Lipoderm® base at a dose of either 5mg/kg TID for 5 days or 10mg/kg TID for 5 days.

After the initial data was analyzed, an additional 15 cats were enrolled and were administered transdermal gabapentin on the ear at 10mg/kg TID. Blood collection occurred prior to gabapentin administration, 24 hours and 5 days post initiating gabapentin.  All serum samples collected were trough samples, frozen at -80 and sent to the University of Tennessee’s Pharmacology Lab for analysis utilizing HPLC-mass spectroscopy.

The project is completed and the data prepared for a manuscript for publication.

Abstract submission for the 2020 ACVIM Forum in June.  Manuscript in current preparation.

An oral abstract is planned for the 2020 ACVIM Forum in June.

Summary prepared for Winn Feline Foundation ©

See also:

Adrian D, Papich MG, et al. The pharmacokinetics of gabapentin in cats. J Vet Intern Med. 2018 Nov;32(6):1996-2002.